You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

ribociclib

( rye-boe-SYE-klib )
Funding:
Exceptional Access Program
  • ribociclib - First-line treatment of hormone receptor positive, human epidermal growth factor receptor 2 (HER 2)-negative unresectable locally advanced breast cancer or metastatic breast cancer, with specific criteria
... Show more tags
Other Name(s): Kisqali™
Appearance: Tablet.    

Drug Monograph

Jun 2020
Table of Contents

Patient Info Sheet

Sep 2019

What it is used for

For treating advanced breast cancer that may not be able to be removed by surgery or has spread to other parts of the body, in combination with another medication



You might also be interested in

Funding & Reimbursement

Several payment sources exist for cancer drugs in Ontario, depending on the drug, disease indication, and how and where it is delivered.

View Funding & Reimbursement

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration